AnaptysBio (NASDAQ:ANAB – Get Rating) had its target price lowered by Wedbush to $24.00 in a research note published on Tuesday, Stock Target Advisor reports. Wedbush also issued estimates for AnaptysBio’s Q4 2023 earnings at ($0.91) EPS, FY2023 earnings at ($3.72) EPS, FY2024 earnings at ($3.01) EPS and FY2025 earnings at ($2.22) EPS.
Separately, Raymond James cut their price target on shares of AnaptysBio from $35.00 to $30.00 in a report on Thursday, September 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, AnaptysBio presently has an average rating of Hold and a consensus price target of $33.33.
AnaptysBio Stock Down 1.9 %
Shares of AnaptysBio stock opened at $24.38 on Tuesday. The firm has a market capitalization of $688.47 million, a P/E ratio of -6.28 and a beta of 0.11. The company has a 50 day moving average price of $22.40 and a 200 day moving average price of $23.78. AnaptysBio has a 52 week low of $18.20 and a 52 week high of $37.89.
Institutional Investors Weigh In On AnaptysBio
A number of hedge funds and other institutional investors have recently made changes to their positions in ANAB. Frazier Life Sciences Management L.P. acquired a new stake in shares of AnaptysBio during the 1st quarter worth approximately $22,259,000. Deerfield Management Company L.P. Series C acquired a new stake in shares of AnaptysBio during the 2nd quarter worth approximately $15,672,000. Assenagon Asset Management S.A. acquired a new stake in AnaptysBio in the 2nd quarter valued at $13,958,000. Deep Track Capital LP acquired a new stake in AnaptysBio in the 1st quarter valued at $13,824,000. Finally, Point72 Asset Management L.P. acquired a new stake in AnaptysBio in the 4th quarter valued at $8,936,000.
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.
- Get a free copy of the StockNews.com research report on AnaptysBio (ANAB)
- It Could Be a September to Remember for These 3 Stocks
- Can Roblox Reverse its Falling Bookings Amid Rising Engagements
- Peak Inflation Sets the Bottom for Brinker International Stock
- Broadcom Bounces From Institutional Bottom
- Affirm is the Underdog Starring in a Spaghetti Western
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.